## Jeffrey Bradley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11545209/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Task Group 174 Report: Utilization of [ 18 F]Fluorodeoxyglucose Positron Emission Tomography ([ 18) Tj ETQq1 I	1 0.78431 3.0	4_rgBT /Ove
2	Clinical prognostic model for older patients with advanced non-small cell lung cancer. Journal of Geriatric Oncology, 2019, 10, 555-559.	1.0	6
3	Delineation of a Cardiac Planning Organ-At-Risk Volume Using Real-Time Magnetic Resonance Imaging for Cardiac Protection in Thoracic and Breast Radiation Therapy. Practical Radiation Oncology, 2019, 9, e298-e306.	2.1	4
4	Non–small-cell Lung Cancer With Brain Metastasis at Presentation. Clinical Lung Cancer, 2018, 19, e373-e379.	2.6	162
5	Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiotherapy and Oncology, 2018, 126, 519-526.	0.6	320
6	Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors?. Seminars in Radiation Oncology, 2018, 28, 114-124.	2.2	7
7	Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. Translational Lung Cancer Research, 2018, 8, 107-115.	2.8	40
8	Toward adaptive proton therapy guided with a mobile helical CT scanner. Radiotherapy and Oncology, 2018, 129, 479-485.	0.6	11
9	The Ever-Increasing Number of Trial Eligibility Criteria: Time to Bend the Curve. Journal of Thoracic Oncology, 2017, 12, 1459-1460.	1.1	3
10	The world's first single-room proton therapy facility: Two-year experience. Practical Radiation Oncology, 2017, 7, e71-e76.	2.1	21
11	Simulated Online Adaptive Magnetic Resonance–Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1078-1086.	0.8	113
12	Learning From Trials on Radiation Dose in Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 748-750.	0.8	2
13	Adjuvant Chemotherapy for Patients with T2NOMO NSCLC. Journal of Thoracic Oncology, 2016, 11, 1729-1735.	1.1	74
14	Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Practical Radiation Oncology, 2015, 5, 149-155.	2.1	78
15	Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Practical Radiation Oncology, 2015, 5, 141-148.	2.1	79
16	Analysis of first recurrence and survival in patients with stage lÂnon–small cell lung cancer treated with surgical resection orÂstereotactic radiation therapy. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1183-1192.e10.	0.8	91
17	A Phase I Study of Temsirolimus and Thoracic Radiation in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 119-123.	2.6	20
18	No Clinically Significant Changes in Pulmonary Function Following Stereotactic Body Radiation Therapy for Early- Stage Peripheral Non-Small Cell Lung Cancer: An Analysis of RTOG 0236. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1092-1099.	0.8	145

JEFFREY BRADLEY

#	Article	IF	CITATIONS
19	Treatment of stage I lung cancer in high-risk and inoperable patients: Comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 692-699	0.8	153
20	A Phase II Comparative Study of Gross Tumor Volume Definition With or Without PET/CT Fusion in Dosimetric Planning for Non–Small-Cell Lung Cancer (NSCLC): Primary Analysis of Radiation Therapy Oncology Group (RTOG) 0515. International Journal of Radiation Oncology Biology Physics, 2012, 82, 435-441.e1.	0.8	99
21	New Territory: Surgical Salvage for Stereotactic Body Radiation Therapy Failures in Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1879-1880.	1.1	11
22	Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA - Journal of the American Medical Association, 2010, 303, 1070.	7.4	2,185
23	Current role of PET in oncology: Potentials and challenges in the management of non-small cell lung cancer. , 2008, , .		1
24	Radiation Pneumonitis and Esophagitis in Thoracic Irradiation. Cancer Treatment and Research, 2008, 128, 43-64.	0.5	36
25	Radiographic Response and Clinical Toxicity Following SBRT for Stage I Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S118-S124.	1.1	50
26	A Review of Radiation Dose Escalation Trials for Non-Small Cell Lung Cancer Within the Radiation Therapy Oncology Group. Seminars in Oncology, 2005, 32, 111-113.	2.2	71
27	Radiation esophagitis: Predictive factors and preventive strategies. Seminars in Radiation Oncology, 2004, 14, 280-286.	2.2	52
28	Impact of FDG-PET on radiation therapy volume delineation in non–small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 78-86.	0.8	534
29	Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1106-1113.	0.8	139